8 terminated. 8 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Terminated 8 |
| Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Leishmaniasis: new trials by email Literature Review of Leishmaniasis trials Research Report on Leishmaniasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial to Determine Efficacy of Fexinidazole in Visceral Leihmaniasis Patients in Sudan Fexinidazole - Visceral Leishmaniasis | Phase 2 | Terminated | Drugs for Neglected Diseases | 14 | 2013-11-01 | 2015-10-30 |
| Safety, Efficacy, and PK of Topical Paromomycin/Gentamicin Cream for Treatment of Cutaneous Leishmaniasis WR 279,396 - Leishmaniasis, Cutaneous | Phase 2 | Terminated | U.S. Army Medical Research and Development Command | 1 | 2013-09-01 | 2019-11-22 |
| WR 279,396 Open Label Treatment Protocol in Tunisia WR 279,396 topical cream - Cutaneous Leishmaniasis | Phase 2 | Terminated | U.S. Army Medical Research and Development Command | 50 | 2011-12-01 | 2014-12-19 |
| Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With VL Liposomal amphotericin B (Ambisome) - Visceral Leishmaniasis | Phase 2 | Terminated | Drugs for Neglected Diseases | 124 | 2009-04-01 | 2016-01-21 |
| Safety and Efficacy of Azithromycin to Treat Cutaneous Leishmaniasis Glucantime®, Zithromax ® - Cutaneous Leishmaniasis | Phase 2 / Phase 3 | Terminated | Ana Rabello | 48 | 2008-06-01 | 2014-10-17 |
| Treatment of Cutaneous Leishmaniasis With a Combination of Miltefosine and Antimony Miltefosine and antimony, Miltefosine alone - Cutaneous Leishmaniasis | Phase 2 | Terminated | Foundation Fader | 19 | 2007-03-01 | 2011-06-27 |
| Topical Treatment of Recalcitrant Ulcerative Old World Leishmaniasis With WR 279,396 Paromomycin +Gentamicin topical cream - Cutaneous Leishmaniasis | Phase 2 | Terminated | U.S. Army Medical Research and Development Command | 1 | 2006-12-20 | 2019-01-22 |
| Miltefosine for Brazilian Visceral Leishmaniasis Miltefosine: initially 2.5 mg/kg/day for 28 days - Kala Azar | Phase 1 / Phase 2 | Terminated | AB Foundation | 80 | 2005-04-01 | 2016-07-12 |
Leishmaniasis, Cutaneous (5) · Leishmaniasis, Visceral (3)
Euglenozoa Infections (8) · Infections (8) · Parasitic Diseases (8) · Protozoan Infections (8) · Vector Borne Diseases (8) · Skin Diseases (5) · Skin Diseases, Infectious (5) · Skin Diseases, Parasitic (5) · Skin and Connective Tissue Diseases (5)
Paromomycin (2) · Antimony (1) · Azithromycin (1) · Meglumine Antimoniate (1) · fexinidazole (1) · liposomal amphotericin B (1) · miltefosine (1)
U.S. Army Medical Research and Development Command (3) · Drugs for Neglected Diseases (2) · AB Foundation (1) · Ana Rabello (1) · Foundation Fader (1)
Brazil (2) · Sudan (2) · United States (2) · Bolivia (1) · Ethiopia (1) · Tunisia (1)
Afif Ben Salah, M.D., Ph.D. (1) · Ahmed M Musa, MD PhD (1) · Ana Rabello, MD PhD (1) · E. AG Khalil, Prof. MD (1) · Isabela Ribeiro, MD (1) · Reynaldo Dietze (1) · Sisay Yifru, MD (1) · Timothy Whitman, DO, USN (1)